CytoMed Therapeutics

Update in progress

GDTC (NasdaqCM)

CytoMed Therapeutics Limited is a pre-clinical biopharma focused on cell-based immunotherapies for cancer and degenerative diseases in Malaysia and Singapore. Its lead CTM-N2D uses expanded gamma delta T cells with NKG2D-ligand–targeting CAR in Phase I trials. Other programs include iPSC-gdNKT, CTM-GDT (allogeneic gamma delta T cells), and CTM-MSC for cartilage injury. Partnerships with Sengkang General Hospital and SunAct Cancer Institute guide trials. Founded 2018, based in Singapore.